ArticleJournal of thoracic disease2025
Impact of platinum-based adjuvant chemotherapy on the effectiveness of IB-IIIA non-small cell lung adenocarcinoma with varying EGFR mutation statuses: a propensity score matching analysis.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Currently, targeted therapies are clinically applied to benefit patients with non-small cell lung cancer (NSCLC), including tyrosine kinase inhibitors (TKIs). However, most tumors inevitably develop resistance to these targeted drugs following treatment, leading to tumor progression or relapse. This study aimed to establish a theoretical basis for adjuvant therapy and further investigate whether platinum-based adjuvant chemotherapy can alleviate the current challenge of TKIs resistance in patients with epidermal growth factor receptor (EGFR) mutations. We retrospectively analyzed the prognostic efficacy of platinum-based adjuvant chemotherapy in patients with stage IB-IIIA non-small cell lung adenocarcinoma based on the mutation status of EGFR using propensity score matching (PSM) analysis. Methods: Among the 50 patients with non-small cell lung adenocarcinoma who underwent complete resection at the Guangzhou Institute of Cancer Research, the Affiliated Cancer Hospital, Guangzhou Medical University, from June 2014 to June 2018, there were 28 cases of wild-type EGFR (WT) and 22 cases of mutant EGFR (MT). PSM was employed to mitigate clinical feature bias between the WT and MT groups, thereby minimizing confounding effects on the results. The study analyzed 5-year disease-free survival (DFS) and 5-year overall survival (OS). Results: Univariate analysis identified smoking as the sole risk factor in the WT group [hazard ratio (HR), 4.963; 95% confidence interval (CI): 1.080-22.811; P=0.04]. No substantial risk factors pertinent to OS were identified in the MT group. Multivariate analysis shows that there were no significant risk factors related to OS in both the WT and MT groups, likely due to the small sample sizes. Prior to PSM, no significant differences in DFS (P=0.10, Cohen's Conclusions: Platinum-based adjuvant chemotherapy does not address the issue of targeted resistance and disease progression in patients with EGFR mutations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.